Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study

被引：12

作者：

Piccaluga, Pier Paolo ^{[1
]}

Malagola, Michele ^{[2
]}

Rondoni, Michela ^{[1
]}

Arpinati, Mario ^{[1
]}

Paolini, Stefania ^{[1
]}

Candoni, Anna ^{[1
]}

Fanin, Renato ^{[3
]}

Messa, Emanuela ^{[4
]}

Pirrotta, Maria Teresa ^{[5
]}

Lauria, Francesco ^{[5
]}

Visani, Giuseppe ^{[6
]}

Alberti, Daniele

Rancati, Francesca

Vinaccia, Vincenza ^{[7
]}

Russo, Domenico

Saglio, Giuseppe ^{[4
]}

Baccarani, Michele ^{[1
]}

Martinelli, Giovanni ^{[1
]}

机构：

[1] Univ Bologna, S Orsola Malpighi Hosp, Inst Hematol & Med Oncol L & A Seragnoli, Via Massarenti 9, I-40138 Bologna, Italy

[2] Univ Brescia, Dept Hematol, Brescia, Italy

[3] Univ Udine, Dept Hematol, Udine, Italy

[4] Univ Torino, Dept Hematol, Orbassano, Turin, Italy

[5] Univ Siena, Dept Hematol, Siena, Italy

[6] Dept Hematol, Pesaro, Italy

[7] Novartis Pharmaceut, Origgio, Italy

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 12期

关键词：

imatinib mesylate; acute myeloid leukemia; c-KIT; PDGFRB; targeted therapy;

D O I：

10.3324/haematol.11345

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.

引用

页码：1721 / 1722

页数：2

共 50 条

[31] Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia
Fujisawa, Shin
Mizuta, Shuichi
Akiyama, Hideki
Ueda, Yasunori
Aoyama, Yasutaka
Hatta, Yoshihiro
Kakihana, Kazuhiko
Dobashi, Nobuaki
Sugiura, Isamu
Onishi, Yasushi
Maeda, Tomoya
Imai, Kiyotoshi
Ohtake, Shigeki
Miyazaki, Yasushi
Ohnishi, Kazunori
Matsuo, Keitaro
Naoe, Tomoki
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (04) : 367 - 374
[32] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Abbott, Brian L.
CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
[33] A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results
Al-Kali, Aref
Tibes, Raoul
Palmer, Jeanne
Alkhateeb, Hassan B.
Patnaik, Mrinal M.
Begna, Kebede H.
Gangat, Naseema
Atherton, Pamela
Liu, Shujun
He, Rong
Hashmi, Shahrukh K.
Litzow, Mark R.
BLOOD, 2018, 132
[34] A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression
Al-Kali, Aref
Tibes, Raoul
Atherton, Pamela
Palmer, Jeanne
Alkhateeb, Hassan B. B.
Patnaik, Mrinal
Begna, Kebede
Gangat, Naseema
Hashmi, Shahrukh
He, Rong
Litzow, Mark
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (03) : 472 - 480
[35] Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study
Abbenante, Mariachiara
Papayannidis, Cristina
Iacobucci, Ilaria
Candoni, Anna
Paolini, Stefania
Malagola, Michele
Emanuela, Ottaviani
Lonetti, Annalisa
Curti, Antonio
Parisi, Sarah
Testoni, Nicoletta
Lama, Barbara
Baccarani, Michele
Martinelli, Giovanni
CANCER RESEARCH, 2011, 71
[36] Daunorubicin, cytarabine and fludarabine (DAF) for the treatment of relapsed/refractory acute myeloid leukemia. Phase II study by the polish adult leukemia group (PALG)
Holowiecki, J
Grosicki, S
Krzemien, S
Skotnicki, A
Warzecha, K
Zdziarska, B
Stella-Holowiecka, B
Krawczyk-Kulis, M
Kopera, M
Wojciechowska, M
BLOOD, 2004, 104 (11) : 210B - 210B
[37] Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: Results of a Japanese phase II clinical study
Morishima, Y
Ogura, M
Nishimura, M
Yazaki, F
Bessho, M
Mizoguchi, H
Chiba, S
Hirai, H
Tauchi, T
Urabe, A
Takahashi, M
Ohnishi, K
Yokozawa, T
Emi, N
Hirano, M
Shimazaki, C
Nakao, S
Kawai, Y
Fujimoto, M
Taguchi, H
Jinnai, I
Ohno, R
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 80 (03) : 261 - 266
[38] Efficacy and Safety of Imatinib Mesylate for Patients in the First Chronic Phase of Chronic Myeloid Leukemia: Results of a Japanese Phase II Clinical Study
Yasuo Morishima
Michinori Ogura
Miki Nishimura
Fumiharu Yazaki
Masami Bessho
Hideaki Mizoguchi
Shigeru Chiba
Hisamaru Hirai
Tetsuzo Tauchi
Akio Urabe
Masatomo Takahashi
Kazunori Ohnishi
Toshiya Yokozawa
Nobuhiko Emi
Masami Hirano
Chihiro Shimazaki
Shinji Nakao
Yasukazu Kawai
Masahiro Fujimoto
Hirokuni Taguchi
Itsuro Jinnai
Ryuzo Ohno
International Journal of Hematology, 2004, 80 : 261 - 266
[39] Lack of Inhibition of AKT Predicts Clinical Resistance to Therapy with Imatinib plus Reinduction Chemotherapy in Relapsed/Refractory c-Kit plus Acute Myeloid Leukemia
Brandwein, Joseph
Hedley, David
Chow, Sue
Schimmer, Aaron D.
Yee, Karen W. L.
Schuh, Andre
Gupta, Vikas
Minden, Mark D.
BLOOD, 2009, 114 (22) : 818 - 818
[40] Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: A Princess Margaret Hospital phase II consortium study
Hotte, SJ
Winquist, EW
Lamont, E
MacKenzie, M
Vokes, E
Chen, EX
Brown, S
Pond, GR
Murgo, A
Siu, LL
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) : 585 - 590

← 1 2 3 4 5 →